Clinical Trials Logo

Filter by:
NCT ID: NCT00426101 Completed - Clinical trials for Hemophagocytic Lymphohistiocytosis

Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004

Start date: January 2004
Phase: Phase 3
Study type: Interventional

Without therapy HLH is often fatal, and often rapidly fatal. The treatment protocol HLH-94 has improved survival markedly as compared to the survival earlier. We now aim to improve survival further.

NCT ID: NCT00424047 Completed - Multiple Myeloma Clinical Trials

A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Start date: January 1, 2003
Phase: Phase 3
Study type: Interventional

To compare the efficacy of oral CC-5013 in combination with oral pulse high-dose dexamethasone to that of placebo and oral high-dose pulse dexamethasone as treatment for subjects with relapsed or refractory multiple myeloma."

NCT ID: NCT00423319 Completed - Pulmonary Embolism Clinical Trials

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

Start date: March 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to learn whether apixaban can prevent the blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism) that sometimes occur after hip replacement surgery and to learn how apixaban compares with enoxaparin in preventing these clots. The safety of apixaban will also be studied

NCT ID: NCT00422058 Completed - Obesity Clinical Trials

The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes

Start date: January 10, 2007
Phase: Phase 2
Study type: Interventional

This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the efficacy of liraglutide to induce body weight loss and the purpose of the extension is to evaluate the long term safety and tolerability of liraglutide. Trial has the following trial periods: A 20-week randomised, double-blind, placebo-controlled, six-armed parallel-group, multi-centre, multinational trial with an open label orlistat comparator arm followed by an 84 week extension period.

NCT ID: NCT00421200 Completed - Hypotension Clinical Trials

Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty

Start date: February 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether Hemospan is superior to Voluven for preventing hypotensive episodes during the perioperative period (from induction of spinal anesthesia until 6 hours after skin closure), and for reducing the incidence of operative and postoperative complications including organ dysfunction and failure until follow-up at one month following surgery. An independent Data Safety Monitoring Board (DSMB) will periodically evaluate the safety data collected during this trial.

NCT ID: NCT00421018 Completed - Allergic Asthma Clinical Trials

Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK)

Start date: November 2006
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether use of exhaled NO (nitric oxide) to regulate the anti-inflammatory treatment leads to increased asthma-related quality of life in patients with allergic asthma

NCT ID: NCT00420927 Completed - Clinical trials for Rheumatoid Arthritis

Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis

OPTIMA
Start date: December 2006
Phase: Phase 4
Study type: Interventional

This study compared the safety and efficacy of combination therapy with adalimumab plus methotrexate (MTX) to that of MTX monotherapy (i.e., placebo plus MTX) in subjects with early rheumatoid arthritis (RA).

NCT ID: NCT00420277 Completed - Hypotension Clinical Trials

Phase III Study of Hemospan® for Treating Hypotension in Hip Arthroplasty

Start date: February 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether Hemospan is superior to Voluven for treatment of hypotensive episodes during the perioperative period (from induction of spinal anesthesia until 6 hours after skin closure), and for reducing the incidence of operative and postoperative complications including organ dysfunction and failure until follow-up at one month following surgery. An independent Data Safety Monitoring Board (DSMB) will periodically evaluate the safety data collected during this trial

NCT ID: NCT00420199 Completed - Clinical trials for Active Rheumatoid Arthritis

A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

Start date: May 2007
Phase: Phase 3
Study type: Interventional

The only trial in participants who are methotrexate-inadequate responders and have active Rheumatoid Arthritis, in which gadolinium-enhanced Magnetic Resonance Imaging; Bone Mineral Density; and biochemical markers of bone, cartilage, and synovial tissue metabolism are used to evaluate early effects (4 months) of Abatacept on inflammation/structural damage. Study will provide valuable mechanism-of-action information on how Abatacept exerts its effects (including on bone) through new techniques.

NCT ID: NCT00419705 Completed - Ischemic Stroke Clinical Trials

Effectiveness and Safety Trial of a New Ischemic Stroke Treatment Within 24 Hours From Stroke Onset (NEST-2)

Start date: December 2006
Phase: Phase 3
Study type: Interventional

The purpose of this pivotal study is to demonstrate safety and effectiveness of the NeuroThera® Laser System (referred to hereafter as NTS) in the treatment of Subjects diagnosed with acute ischemic stroke. The initiation of NTS treatment must be feasible for each Subject within 24 hours of stroke onset.